ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
Background and purpose Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods Radiotherapy (50.4 Gy/28...
Main Authors: | Wilson, J, Fokas, E, Dutton, S, Hawkins, M, al., E |
---|---|
格式: | Journal article |
出版: |
Elsevier
2016
|
相似书籍
-
ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
由: Wilson, J, et al.
出版: (2017) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
由: Brunner, T, et al.
出版: (2008) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
由: Brunner, T, et al.
出版: (2008) -
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
由: Brunner, T, et al.
出版: (2008) -
HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
由: Unaí Tupinambás, et al.